Rubiamara Mauricio Sousa

Prof. Rubiamara Mauricio Sousa


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Processes
Verified
Journal Article
Open access
PDF file
Jefferson Romáryo Duarte da LuzJefferson Romáryo Duarte da Luz
Jefferson Romáryo Duarte da Luz
Jorge A. LópezJorge A. López
Jorge A. López
MFMacelia Pinheiro Ferreira
Macelia Pinheiro Ferreira
RSRubiamara Mauricio Sousa
Rubiamara Mauricio Sousa
Saulo Victor SilvaSaulo Victor Silva
Saulo Victor Silva
GAGabriel Araujo-Silva
Gabriel Araujo-Silva
The balance between embolic risk and bleeding represents a clinical challenge in cancer patient treatment, encouraging studies on adjuvant oncologic treatments. Thereby, this study evaluated the in vitro effect of green tea extract (GTE) and epigallocatechin-3-gallate (EGCG) on hemostasis modulation and the antineoplastic effect on melanoma cells (B16-F10) by applying platelet aggregation, angiogenesis and viability cell assays. The results displayed a significant platelet antiaggregant effect, corresponding to 50 and 80% for the extract and EGCG, respectively, compared to the negative control. Furthermore, both GTE and EGCG exhibited antitumor effects by reducing melanoma cell growth by 25 and 50%, respectively, verified by cellular apoptosis. Regarding angiogenesis, these substances inhibited blood vessel formation, reaching about 25% and 99% for GTE and EGCG at 100 μg/mL, respectively. Moreover, TNF-α cell stimulation evidenced VEGF and IL-8 secretion inhibition at 55 and 20% with GTE, while EGCG promoted an inhibition around 78% for both VEGF and IL-8. The results indicate the promising performance of GTE and EGCG as an option for treating cancer and its side effects. Nonetheless, further studies are required to elucidate their action mechanism on clotting, cell death and angiogenesis.

27 May 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
Jefferson Romáryo Duarte da LuzJefferson Romáryo Duarte da Luz
Jefferson Romáryo Duarte da Luz
EBEder Barbosa
Eder Barbosa
RSRubiamara Mauricio Sousa
Rubiamara Mauricio Sousa
MOMaria Lúcia de Azevedo Oliveira
Maria Lúcia de Azevedo Oliveira
MDMarcela Dias
Marcela Dias
GAGabriel Araujo-Silva
Gabriel Araujo-Silva
The antioxidant capacity and modulation of oxidative stress by industrially processed açaí pulp extract from the Amazon (APEA) and its major anthocyanins, cyanidin 3-glucoside (C3G) and cyanidin-3-O-rutinoside (C3R), were evaluated as potential strategies for preventing cardiovascular diseases. The APEA was chemically characterized using ultrafast liquid chromatography-mass spectrometry (UFLC-MS), which revealed six main phenolic compounds. Notably, 9-(2,3-dihydroxypropoxy)-9-oxononanoic acid, acanthoside B, roseoside, cinchonine, and nonanedioate were identified for the first time in açaí extracts. In vitro antioxidant assays demonstrated that APEA exhibited strong DPPH- and ABTS-radical-scavenging activities (up to 80% inhibition and 65 mmol TE/100g DW, respectively) and showed ferrous- and copper-ion-chelating activities comparable to those of EDTA-Na2 at higher concentrations (up to 95% inhibition). Hydroxyl and superoxide radical scavenging activities reached 80% inhibition, similar to that of ascorbic acid. In H2O2-treated H9c2 cardiomyocytes, APEA significantly reduced the intracellular ROS levels by 46.9%, comparable to the effect of N-acetylcysteine. APEA also attenuated menadione-induced oxidative stress in H9c2 cells, as shown by a significant reduction in CellROX fluorescence (p < 0.05). In vivo, APEA (100 mg/kg) significantly reduced CCl-induced hepatic lipid peroxidation (MDA levels), restored glutathione (GSH), and increased the antioxidant enzymes CAT, GPx, and SOD, demonstrating superior effects to C3G and C3R, especially after 21 days of treatment (p < 0.001). These findings suggest that Amazonian açaí pulp (APEA) retains potent antioxidant activity after industrial processing, with protective effects against oxidative damage in cardiomyocytes and hepatic tissue, highlighting its potential as a functional food ingredient with cardioprotective and hepatoprotective properties.

7 November 2025 in Molecules
Verified
Journal Article
Open access
PDF file
MOMaria Lúcia de Azevedo Oliveira
Maria Lúcia de Azevedo Oliveira
RSRubiamara Mauricio Sousa
Rubiamara Mauricio Sousa
EBEder Barbosa
Eder Barbosa
OGOny Araujo Galdino
Ony Araujo Galdino
DDDuanny Lorena Aires Dantas
Duanny Lorena Aires Dantas
Maria Graças AlmeidaMaria Graças Almeida
Maria Graças Almeida
Momordica charantia L. (Cucurbitaceae) has been widely recognized for its pharmacological potential, although studies on its leaves remain scarce. In this study, the hydroethanolic leaf extract (MCHLE) was chemically characterized by LC–MS/MS, revealing the presence of octopamine, ferulate, vitexin-2-O-rhamnoside, and other bioactive phenolics. Toxicological evaluation in Wistar rats demonstrated that both acute (2000 mg/kg) and repeated oral administration (up to 400 mg/kg for 28 days) caused no clinical or behavioral signs of toxicity. Notably, treatment significantly reduced glucose and cholesterol levels, in addition to attenuating lipid peroxidation and enhancing antioxidant defenses. In vivo, MCHLE inhibited leukocyte and neutrophil infiltration in the LPS-induced peritonitis model, with efficacy comparable to dexamethasone. It also reduced TNF-α secretion and nitric oxide generation in peritoneal fluids. In vitro assays with LPS-stimulated RAW 264.7 macrophages confirmed these effects, showing dose-dependent inhibition of TNF-α, IL-1β, and NO production. Gene expression analysis further demonstrated downregulation of TNF-α and MAPK, with marked suppression of NF-κB transcripts. Collectively, these results suggest that MCHLE exerts anti-inflammatory activity by targeting both mediator release and upstream signaling pathways, while maintaining a favorable safety profile, supporting its potential for further investigation as a promising source of bioactive compounds.

28 August 2025 in Revista chilena de nutrición
Verified
Journal Article
Closed access
Saulo Victor SilvaSaulo Victor Silva
Saulo Victor Silva
MFMacelia Ferreira
Macelia Ferreira
RSRubiamara Mauricio Sousa
Rubiamara Mauricio Sousa
Jefferson Romáryo Duarte da LuzJefferson Romáryo Duarte da Luz
Jefferson Romáryo Duarte da Luz
KSKarla Simone Costa de Souza
Karla Simone Costa de Souza
Maria Graças AlmeidaMaria Graças Almeida
Maria Graças Almeida
Down syndrome (DS) is marked by oxidative stress due to an imbalance between reactive oxygen species (ROS) and antioxidant enzymes. Antioxidant compounds like coenzyme Q10 (CoQ10) and zinc (Zn) may mitigate cellular imbalances induced by elevated ROS levels. This double-blind, randomized clinical trial assessed the effects of CoQ10 supplementation, alone and in combination with Zn, in 20 children with DS aged 2–9 years. We evaluated biochemical parameters, dietary intake, anthropometric measures, lipid peroxidation, and antioxidant potential through the enzymatic activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GSH), alongside serum Zn levels. Our findings revealed that participants had serum Zn concentrations below recommended levels. Supplementation with Zn alongside CoQ10 enhanced the antioxidant efficacy of CoQ10, yielding positive outcomes. This study highlights the prevalence of Zn deficiency in children with DS and suggests that CoQ10 and Zn supplementation may improve antioxidant activity, decrease lipid peroxidation, and preserve antioxidant enzyme function.